Cerevel Therapeutics Holdings
- Pharmaceutical Preparations
- Cambridge, Massachusetts
Compensation history
Top executives at Cerevel Therapeutics Holdings received an average of $4M per person in annual compensation from 2019 to 2021.
Average pay of disclosed executives at Cerevel Therapeutics Holdings
By year
- 2021
NC$8MN. Anthony ColesChairperson and Chief Executive OfficerAC$5MAbraham CeesayPresidentKY$4MKathy YiFormer Chief Financial OfficerRS$3MRaymond SanchezChief Medical OfficerSA$3MScott AkamineChief Legal Officer and Corporate SecretaryMB$1MMark BodenraderInterim Chief Financial Officer, Vice President, Finance and Chief Accounting Officer
Executives
We found nine executives who work or worked at Cerevel Therapeutics Holdings.
N Coles
Cerevel Therapeutics Holdings
Chief Executive Officer
Mark Bodenrader
Cerevel Therapeutics Holdings
Chief Financial Officer
Kathy Yi
Cerevel Therapeutics Holdings
Chief Financial Officer
Abraham Ceesay
Cerevel Therapeutics Holdings
President
Raymond Sanchez
Cerevel Therapeutics Holdings
Chief Medical Officer
Scott Akamine
Cerevel Therapeutics Holdings
Chief Legal Officer
John Renger
Cerevel Therapeutics Holdings
Chief Scientific Officer
Kathleen MA
Cerevel Therapeutics Holdings
Chief Corporate Affairs Officer
News
About Cerevel Therapeutics Holdings
- Industry classifications
- DivisionManufacturing
- Major groupChemicals And Allied Products
- Industry groupDrugs
- IndustryPharmaceutical Preparations
- Address222 Jacobs Street, Suite 200, Cambridge, Massachusetts 02141
- Phone844-304-2048
- Fiscal year endDecember 31
- Former names
- ARYA Sciences Acquisition Corp IIUntil October 25, 2020
Source: SEC filings on April 28, 2022 and April 28, 2021.